**Alert**

Intravenous paracetamol should be considered a high-risk medicine when administered to infants and young children. Use of paracetamol should always be preceded by a comprehensive risk assessment and reviewed every 24 hours. Safety data for paracetamol in extreme preterm infants (< 28 weeks) is limited. It should be used with caution, particularly in the treatment of patent ductus arteriosus.

**Indication**

Analgesia  
Antipyretic  
Adjunct to post-operative analgesia  
Treatment of patent ductus arteriosus (PDA)

**Action**

Centrally acting analgesic and antipyretic with minimal anti-inflammatory properties. The mechanism of action of paracetamol in reducing pain is not completely defined. Potential mechanisms include inhibition of central prostaglandin synthesis and inhibition of the cyclooxygenase (COX) isoenzyme, particularly the COX-2 isoform.

**Drug Type**

Non-narcotic analgesic and antipyretic.

**Trade Name**

Intravenous: Paracetamol Actavis; Paracetamol ACT; Paracetamol BNM; Paracetamol IV Pfizer; Paracetamol Kabi; Paracetamol-AFT; Paramat  
Oral: Dymadon, Febridol, Panadol (Children)

**Presentation**

IV: 500 mg/50 ml (10 mg/ml) vial  
Oral: 100 mg/mL drops

**Dosage/Interval**

<table>
<thead>
<tr>
<th>Weight*</th>
<th>Loading</th>
<th>Maintenance</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;2.0 kg</td>
<td>15 mg/kg</td>
<td>7.5 mg/kg every 6 hours</td>
</tr>
<tr>
<td>2.0 – 3.0 kg</td>
<td>15 mg/kg</td>
<td>10 mg/kg every 6 hours</td>
</tr>
<tr>
<td>&gt;3.0 kg</td>
<td>20 mg/kg</td>
<td>10 mg/kg every 6 hours</td>
</tr>
</tbody>
</table>

*Current/best weight

**Patent Ductus Arteriosus (treatment course 3-7 days with 48-hourly monitoring of liver function)**

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Loading</th>
<th>Maintenance</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥28 weeks CGA/PMA and ≥1000 g*</td>
<td>15 mg/kg</td>
<td>15 mg/kg every 6 hours</td>
</tr>
<tr>
<td>&lt;28 weeks and/or &lt;1000 g*</td>
<td>15 mg/kg</td>
<td>7.5 mg/kg every 6 hours**</td>
</tr>
</tbody>
</table>

*Current/best weight  
**Higher maintenance doses (15 mg/kg) in extremely premature infants have been used but there is limited safety data.

**Maximum daily dose**

60 mg/kg/day

**Route**

IV, oral, rectal

**Preparation/Dilution**

Intravenous: Use undiluted. Can be diluted to 2 mg/ml for use in ELBW infants using sodium chloride 0.9% or glucose 5%. If diluted, the solution should be used immediately.

**Administration**

Intravenous:  
Administer over 15 minutes via syringe driver.  
Oral:  
Can be given with or without feeds. Shake bottle well before measuring dose.  
Rectal:  
Dilute oral mixture 1:1 with water for rectal doses. Low dose suppositories are not commercially available but can be prepared by selected pharmacy departments. Do not cut suppositories to make part rectal dose.

**Monitoring**

Monitor hepatic and renal function. If signs of acute liver injury (example, raised ALT >50 IU/L) – refer to acetylcysteine formulary and contact Poisons Information Centre (13 11 26 for New South Wales) or local toxicology service.

**Contraindications**

Hypersensitivity to paracetamol, active liver disease.

**Precautions**

Hepatic impairment, renal impairment, sepsis, dehydration
### Drug Interactions

Paracetamol absorption is increased by substances that increase gastric emptying. Paracetamol absorption is decreased by substances that decrease gastric emptying. Paracetamol may increase chloramphenicol concentrations. The risk of paracetamol toxicity may be increased in patients receiving other potentially hepatotoxic drugs or drugs that induce liver microsomal enzymes such as anticonvulsant agents.

### Adverse Reactions

Vomiting, fever, rash, neutropenia, leucopenia, thrombocytopenia. May cause liver toxicity at high plasma concentrations.

### Compatibility

Sodium chloride 0.9%, glucose 5%

### Incompatibility

Do not mix with any other intravenous fluids or medications.

### Stability

Vials should be used immediately after opening. Any unused solution should be discarded. After dilution in 0.9% sodium chloride or 5% glucose do not store for more than 1 hour (infusion time included).

### Storage

IV: Do not store above 30°C. Do not refrigerate or freeze.
Oral: Store below 25°C.

### Special Comments

Preterm infants may be at increased risk of paracetamol toxicity. Review indications if IV paracetamol is needed for more than 48 hours.
Antidote of choice for overdose is acetylcysteine IV infusion.
Rectal bioavailability is variable depending on the formulation used. Oral or intravenous routes are preferred.

### Evidence summary

**Efficacy and safety (analgesia/adjuvant to post-operative analgesia)**

A systematic review of nine reported comparisons in 728 infants of paracetamol versus placebo or other pain-reducing interventions. Paracetamol for heel lance did not reduce pain when compared with EMLA cream. Paracetamol use was associated with a stronger response to pain than was seen with glucose. Paracetamol did not reduce pain in infants exposed to vacuum extraction or forceps at birth and their response to a subsequent heel lance at two to three days of life was increased compared with placebo. For eye examination, paracetamol was effective in reducing pain compared with water in one study, but the pain response was stronger among paracetamol-treated infants than in infants given 24% sucrose. In infants treated with paracetamol (30 mg/kg/day) and morphine compared with morphine alone, the total amount of morphine required during the first 48 hours following major surgery to the chest or the abdomen was less in the paracetamol group.

Recommendation: The paucity and low quality of existing data do not provide sufficient evidence to establish the role of paracetamol in reducing the effects of painful procedures in neonates. Paracetamol given after assisted vaginal birth may increase the response to later painful exposures. Paracetamol may reduce the total need for morphine following major surgery, and for this aspect of paracetamol use, further research is needed (LOE I GOR B).

**Efficacy and safety (PDA)**

One published, randomised, controlled trial has compared paracetamol with placebo. In 48 preterm infants intravenous paracetamol (20 mg/kg loading; 7.5 mg/kg every 6 hours) was compared with no paracetamol within the first 24 hours of life; with a higher closure rate and shorter time to closure in the treatment arm and no reported adverse events. A systematic review of two randomised, controlled trials reported comparisons of oral paracetamol versus oral ibuprofen for the treatment of an echocardiographically diagnosed PDA in 250 infants born preterm (≤ 34 weeks postmenstrual age [PMA]). The success rate for paracetamol to close a PDA was similar to that of ibuprofen. Adverse events were similar in both groups. However, in general, the trends favoured infants who received paracetamol and additionally the adverse events were lower in the paracetamol group. A second systematic review of studies involving the use of paracetamol in preterm infants reported on sixteen studies: Two randomised controlled trials and 14 uncontrolled studies. The quality of selected studies was rated as poor. The majority of studies used 15 mg/kg every 6 hours for 3–7 days. Proportion meta-analysis of uncontrolled studies demonstrated a pooled ductal closure rate of 49% (95% CI 29% to 69%) and 76% (95% CI 61% to 88%) after 3 and 6 days of treatment with paracetamol, respectively. A third, randomised,
controlled trial involving 77 preterm infants has since been published comparing oral paracetamol and NSAIDs (intravenous indomethacin) with similar closure rates and no reported adverse events\(^8\). A small, randomised, controlled trial involving 18 preterm infants showed that closure rates were similar using oral versus intravenous paracetamol with no reported adverse events\(^9\).

Recommendation: The efficacy and safety of paracetamol appears to be comparable with ibuprofen. These results should be interpreted with caution, taking into account the non-optimal quality of the studies analysed and the limited number of neonates treated with paracetamol so far\(^6,7\) (LOE I GOR B).

Pharmacokinetics

Model-based dosing regimen of intravenous paracetamol aiming for a target paracetamol concentration of 9 mg/l based on population pharmacokinetic analysis from preterm neonates to adults, including 108 neonates (post-natal age 1–76 days, gestational age 27–42 weeks)\(^1\):

- BW 0.5 kg – Loading 11.2 mg/kg; maintenance q6h 5.1 mg/kg
- BW 1.0 kg – Loading 12.1 mg/kg; maintenance q6h 6.0 mg/kg
- BW 1.5 kg – Loading 12.2 mg/kg; maintenance q6h 6.8 mg/kg
- BW 2.0 kg – Loading 13.3 mg/kg; maintenance q6h 7.4 mg/kg
- BW 3.0 kg – Loading 12.8 mg/kg; maintenance q6h 8.5 mg/kg
- BW 5.0 kg – Loading 13.5 mg/kg; maintenance q6h 10.4 mg/kg

NB. The above numbers can be converted to any target concentration by dividing by 9 and multiplying by the desired target concentration. The dosing schedule in this formulary is based on a target paracetamol concentration of 11 mg/l.

Population pharmacokinetic analysis of 943 paracetamol observations from 158 neonates (27–45 weeks' postmenstrual age [PMA]) showed a mean paracetamol serum concentration of 11 mg/l is predicted in neonates of 32–44 weeks' PMA given a standard dose of intravenous paracetamol of 10 mg/kg every 6 hours\(^2\).

A population pharmacokinetic analysis of acetaminophen time-concentration profiles in 283 children (124 aged ≤ 6 months) reported that a mean, steady state, target concentration greater than 10 mg/l at trough can be achieved by an oral dose of 25 mg/kg/day in premature neonates at 30 weeks' post-conception, 45 mg/kg/day at 34 weeks' gestation, 60 mg/kg/day at term. Similar concentrations can be achieved with maintenance rectal doses of 25 (capsule suppository) or 30 (triglyceride suppository) mg/kg/day in premature neonates at 30 weeks' gestation, increasing to 90 (capsule suppository) or 120 (triglyceride suppository) mg/kg/day at 6 months\(^3\).

Hepatic toxicity

Individual cases with hepatic toxicity related to paracetamol in newborns have been reported. Overall, the number of cases reported is limited to significant overdoses (75–446 mg/kg), most commonly as a result of an in-hospital, 10-fold drug error\(^10\). In infants and children, hepatotoxicity has been reported over a wide dosage range (60–420 mg/kg/day for 1–42 days)\(^11\).

References


